<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="gan" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">gan</book-part-id>
      <title-group>
        <title>Giant Axonal Neuropathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Kuhlenb&#x000e4;umer</surname>
            <given-names>Gregor</given-names>
          </name>
          <xref ref-type="aff" rid="gan.AFF1"/>
          <degrees>MD, PhD</degrees>
          <email>g.kuhlenbaeumer@neurologie.uni-kiel.de</email>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Timmerman</surname>
            <given-names>Vincent</given-names>
          </name>
          <xref ref-type="aff" rid="gan.AFF2"/>
          <degrees>PhD</degrees>
          <email>vincent.timmerman@molgen.vib-ua.be</email>
        </contrib>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Bomont</surname>
            <given-names>Pascale</given-names>
          </name>
          <xref ref-type="aff" rid="gan.AFF3"/>
          <degrees>PhD</degrees>
          <email>pascale.bomont@inserm.fr</email>
        </contrib>
      </contrib-group>
      <aff id="gan.AFF1">Department of Neurology <break/>University of Kiel<break/>Kiel, Germany</aff>
      <aff id="gan.AFF2">VIB Department of Molecular Genetics<break/>University of Antwerp <break/>Institute Born-Bunge<break/>Antwerp, Belgium </aff>
      <aff id="gan.AFF3">Avenir-Atip Team<break/>Institute for Neurosciences of Montpellier<break/>INSERM-Unit 1051<break/>Montpellier, France</aff>
      <pub-history>
        <date iso-8601-date="2003-01-09" date-type="created">
          <day>09</day>
          <month>01</month>
          <year>2003</year>
        </date>
        <date iso-8601-date="2014-10-09" date-type="updated">
          <day>09</day>
          <month>10</month>
          <year>2014</year>
        </date>
        <date iso-8601-date="2009-08-11" date-type="revised">
          <day>11</day>
          <month>08</month>
          <year>2009</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="prion" document-type="chapter">Genetic Prion Diseases</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="glut1" document-type="chapter">Glucose Transporter Type 1 Deficiency Syndrome</related-object>
      <abstract id="gan.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Giant axonal neuropathy (GAN) is an early-onset fatal neurodegenerative disorder. GAN starts as severe peripheral motor and sensory neuropathy during infancy and evolves into central nervous system impairment (intellectual disability, seizures, cerebellar signs, and pyramidal tract signs). Most individuals become wheelchair dependent in the second decade of life and eventually bedridden with severe polyneuropathy, ataxia, and dementia. Death usually occurs in the third decade. </p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of GAN is suggested by clinical findings and the results of nerve conduction velocity (NCV) studies and brain MRI. The diagnosis is established in individuals with biallelic pathogenic variants in <italic toggle="yes">GAN</italic> (encoding gigaxonin, a subunit of an E3 ubiquitin ligase) or decreased quantities of gigaxonin on immunodiagnostic testing. Nerve biopsy, the former diagnostic modality, is no longer routinely used.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations</italic>: A multidisciplinary team including (pediatric) neurologists, orthopedic surgeons, physiotherapists, psychologists, and speech and occupational therapists is recommended; goals are to optimize intellectual and physical development through speech therapy to improve communication, occupational therapy to maximize independence in activities of daily living, physiotherapy to preserve mobility as long as possible, and early intervention and special education; orthopedic surgery as needed for foot deformities; ophthalmologic treatment as needed for diplopia. </p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> For wheelchair-bound or bedridden individuals, prophylaxis and frequent examination for decubitus ulcers. </p>
          <p><italic toggle="yes">Surveillance:</italic> At least yearly reassessment of intellectual abilities, peripheral neuropathy, ataxia, spasticity, and cranial nerve dysfunction. </p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>GAN is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Individuals with GAN have not been known to reproduce, most likely because they die at a young age. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the <italic toggle="yes">GAN</italic> pathogenic variants in a family are known. </p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="gan.Diagnosis">
        <title>Diagnosis</title>
        <sec id="gan.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>The diagnosis of giant axonal neuropathy (GAN) is suggested in individuals with the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Severe early-onset peripheral motor and sensory neuropathy. Nerve conduction studies often show normal to moderately reduced nerve conduction velocity (NCV) but severely reduced compound motor action potentials and absent sensory nerve action potentials. </p>
            </list-item>
            <list-item>
              <p>Tightly curled lackluster hair that differs markedly from that of the parents. Note: Microscopic examination of unstained hair shows abnormal variation in shaft diameter and twisting (pili torti) similar to the abnormality seen in Menkes disease (see <related-object link-type="booklink" source-id="gene" document-id="menkes" document-type="chapter"><italic toggle="yes">ATP7A</italic>-Related Copper Transport Disorders</related-object>). The hair in individuals with GAN also shows longitudinal grooves on scanning electron microscopy [<xref ref-type="bibr" rid="gan.REF.kennerson.2010.343">Kennerson et al 2010</xref>, <xref ref-type="bibr" rid="gan.REF.kaler.2011.15">Kaler 2011</xref>, <xref ref-type="bibr" rid="gan.REF.yi.2012.1794">Yi et al 2012</xref>].</p>
            </list-item>
            <list-item>
              <p>Central nervous system involvement including intellectual disability, cerebellar signs (ataxia, nystagmus, dysarthria), and pyramidal tract signs</p>
            </list-item>
            <list-item>
              <p>White matter abnormalities on brain MRI. High signals on T<sub>2</sub> sequences in the anterior and posterior periventricular regions as well as the cerebellar white matter are often seen [<xref ref-type="bibr" rid="gan.REF.demir.2005.825">Demir et al 2005</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="gan.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of GAN is established in a proband by identification of either biallelic pathogenic variants in <italic toggle="yes">GAN,</italic> the gene encoding the protein gigaxonin [<xref ref-type="bibr" rid="gan.REF.bomont.2000.370">Bomont et al 2000</xref>] (see <xref ref-type="table" rid="gan.T.summary_of_molecular_genetic_testi">Table 1</xref>) or decreased amounts of gigaxonin on immunodiagnostic testing. </p>
          <p>
            <bold>Molecular genetic testing</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>One genetic testing strategy is sequence analysis of <italic toggle="yes">GAN,</italic> followed by deletion/duplication analysis if only one or no pathogenic variant is found.</p>
            </list-item>
            <list-item>
              <p>An alternative genetic testing strategy is use of a multi-gene panel that includes <italic toggle="yes">GAN</italic> and other genes of interest (see <xref ref-type="sec" rid="gan.Differential_Diagnosis">Differential Diagnosis</xref>). Note: The genes included and the methods used in multi-gene panels vary by laboratory and over time. </p>
            </list-item>
          </list>
          <table-wrap id="gan.T.summary_of_molecular_genetic_testi" position="anchor" orientation="portrait">
            <label>Table 1.</label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Giant Axonal Neuropathy</p>
            </caption>
            <table>
              <tbody>
                <tr>
                  <th id="hd_b_gan.T.summary_of_molecular_genetic_testi_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_b_gan.T.summary_of_molecular_genetic_testi_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_b_gan.T.summary_of_molecular_genetic_testi_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant Detectable by this Method</th>
                </tr>
                <tr>
                  <td headers="hd_b_gan.T.summary_of_molecular_genetic_testi_1_1_1_1" align="left" valign="middle" rowspan="2" colspan="1">
                    <italic toggle="yes">GAN</italic>
                  </td>
                  <td headers="hd_b_gan.T.summary_of_molecular_genetic_testi_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>2</sup></td>
                  <td headers="hd_b_gan.T.summary_of_molecular_genetic_testi_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">70%-90%&#x000a0;<sup>3</sup></td>
                </tr>
                <tr>
                  <td headers="hd_b_gan.T.summary_of_molecular_genetic_testi_1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">Deletion/duplication analysis&#x000a0;<sup>4</sup></td>
                  <td headers="hd_b_gan.T.summary_of_molecular_genetic_testi_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">Unknown&#x000a0;<sup>5</sup>
</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="gan.TF.1">
                <label>1.</label>
                <p>See <related-object source-id="gene" document-id="gan" object-id="gan.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="gan.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene. </p>
              </fn>
              <fn id="gan.TF.1.1">
                <label>2.</label>
                <p>Sequence analysis detects variants that are benign, likely benign, of unknown significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exonic or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="gan.TF.1.2">
                <label>3.</label>
                <p>Using sequence analysis, <xref ref-type="bibr" rid="gan.REF.bomont.2000.370">Bomont et al [2000]</xref> identified pathogenic variants in all 22 families analyzed. Except for two heterozygous pathogenic variants in two families, all pathogenic variants (95% of total pathogenic variants) were identified within the 11 exons of <italic toggle="yes">GAN</italic>. This indicates that the failure to find a pathogenic variant most likely resulted from limitations of the testing methodology rather than genetic locus heterogeneity. Pathogenic variants in these families may be located in regions of the gene that were not sequenced (e.g., introns) or may be of a mutation type not detectable by sequence analysis (e.g., larger deletions, duplications). </p>
              </fn>
              <fn id="gan.TF.1.3">
                <label>4.</label>
                <p>Testing that identifies exonic or whole-gene deletions/duplications are not detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA. Included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) (also known as CGH array) that includes this gene/chromosome segment.</p>
              </fn>
              <fn id="gan.TF.1.4">
                <label>5.</label>
                <p>Among the 60 total distinct pathogenic variants identified to date, four large deletions have been reported. Deletions can encompass almost the entire gene [<xref ref-type="bibr" rid="gan.REF.buysse.2010.2802">Buysse et al 2010</xref>] or only a few exons [<xref ref-type="bibr" rid="gan.REF.boizot.2014.1">Boizot et al 2014</xref>]. </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Immunodetection of gigaxonin.</bold> With the increased identification of large deletions within <italic toggle="yes">GAN</italic>, the risk of false negative results with genomic testing (e.g., multi-gene panels and exome sequencing) becomes significant. Thus, an alternative diagnostic test was needed to allow detection of all types of mutations, including large deletions and those that affect gene expression as well (i.e., mutations in the promoter, regulatory regions within introns). </p>
          <p>To meet these needs a new immunodiagnostic test was developed using a specific antibody to quantitate gigaxonin in immortalized lymphoblast cells (derived from blood) [<xref ref-type="bibr" rid="gan.REF.boizot.2014.1">Boizot et al 2014</xref>]. In several individuals with molecularly confirmed GAN markedly decreased quantities of mutant gigaxonin were observed (mean residual value was 13.1% of control values). Subsequently, in seven families with a sensorimotor axonal neuropathy of unknown etiology that resembled GAN/CMT2, this test was fully penetrant and specific for GAN: all individuals with low levels of gigaxonin in the range observed in GAN (and only those individuals) were subsequently identified to have biallelic pathogenic variants in <italic toggle="yes">GAN</italic> by sequence analysis or deletion/duplication analysis. </p>
          <p>In summary, this new test holds promise a fast diagnostic tool that may be used prior to or in concert with the molecular genetic testing of <italic toggle="yes">GAN</italic>. Of note, studies on a larger cohort are needed to confirm its prognostic value. Additionally, the test methods are being adapted to allow testing of fresh blood samples (rather than immortalized cells derived from patient blood samples).</p>
        </sec>
      </sec>
      <sec id="gan.Clinical_Description">
        <title>Clinical Characteristics</title>
        <sec id="gan.Natural_History">
          <title>Clinical Description</title>
          <p>Giant axonal neuropathy (GAN) is a neurodegenerative disorder affecting both the peripheral and central nervous systems. GAN is classified within the hereditary motor and sensory neuropathies.</p>
          <p>GAN typically begins before age five years and progresses to death, usually by early adulthood. Milder forms of the disease have been reported with later age of onset, extended survival, or modest deterioration of central nervous system [<xref ref-type="bibr" rid="gan.REF.benhamida.1990.245">Ben Hamida et al 1990</xref>, <xref ref-type="bibr" rid="gan.REF.zemmouri.2000.592">Zemmouri et al 2000</xref>]. Individuals present with a motor and sensory peripheral neuropathy that may also involve the cranial nerves, resulting in facial weakness, optic atrophy, and ophthalmoplegia. Tendon reflexes are often absent; Babinski's sign may be present as a result of CNS involvement. </p>
          <p>The majority of affected individuals show signs of CNS involvement including intellectual disability, cerebellar signs (ataxia, nystagmus, dysarthria), epileptic seizures, and signs of pyramidal tract damage.</p>
          <p>Most affected individuals have characteristic tightly curled lackluster hair, unlike their parents.</p>
          <p>Most affected individuals become wheelchair dependent in the second decade of life and die in the third decade. They eventually become bedridden with severe polyneuropathy, ataxia, and dementia. Death results from secondary complications, such as respiratory failure. </p>
          <p><bold>Other findings.</bold> Auditory brain stem evoked responses, visual evoked responses, and somatosensory evoked responses are often abnormal.</p>
          <p>EEG often shows increased slow wave activity.</p>
          <p><bold>Neuroimaging.</bold> Brain MRI and magnetic resonance spectroscopy (MRS) in an individual age 11 years revealed evidence of significant demyelination and glial proliferation in the white matter, but no neuroaxonal loss [<xref ref-type="bibr" rid="gan.REF.alkan.2003.371">Alkan et al 2003</xref>]. MRS of another individual at ages nine and 12 years revealed signs of damage or loss of axons accompanied by acute demyelination in the white matter and generalized proliferation of glial cells in both gray and white matter [<xref ref-type="bibr" rid="gan.REF.brockmann.2003.45">Brockmann et al 2003</xref>].</p>
        </sec>
        <sec id="gan.Histopathology">
          <title>Histopathology</title>
          <p><bold>Peripheral nerve biopsy</bold> exhibits reduced density of nerve fibers and the presence of giant axons (i.e., distorted nerve fibers with large axonal swellings &#x02264;50 &#x000b5;m) [<xref ref-type="bibr" rid="gan.REF.asbury.1972.237">Asbury et al 1972</xref>, <xref ref-type="bibr" rid="gan.REF.berg.1972.894">Berg et al 1972</xref>]. </p>
          <p>Ultrastructural examination of giant axons reveals severe disorganization of neurofilaments (NFs), including loss of parallel orientation along the axons and abnormal clumping [<xref ref-type="bibr" rid="gan.REF.donaghy.1988.991">Donaghy et al 1988</xref>]. </p>
          <p>Reduction of myelin thickness in giant axons, onion-bulb formation by multiple Schwann cell processes, and segmental demyelination and remyelination may also suggest Schwann cell dysfunction.</p>
          <p>Note: Giant axons and NF accumulation, initially described as specific hallmarks for GAN, are now known to occur in several forms of the peripheral neuropathy, including the Charcot-Marie-Tooth disease forms <related-object link-type="booklink" source-id="gene" document-id="cmt2e" document-type="chapter">CMT2E</related-object> and <related-object link-type="booklink" source-id="gene" document-id="cmt4c" document-type="chapter">CMT4C</related-object>. </p>
          <p>Thus, peripheral nerve biopsy examination is not sufficient to establish the diagnosis of GAN. </p>
          <p><bold>Central nervous system.</bold> Giant axons are also observed in the cerebral cortex and other parts of the brain in persons with GAN.</p>
        </sec>
        <sec id="gan.Pathophysiology">
          <title>Pathophysiology</title>
          <p>Structural examination of giant axons often reveals exclusion of mitochondria, endoplasmic reticulum vesicles, and microtubules (MTs) from NF-enriched regions. </p>
          <p>Intermediate filament (IF) disorganization in GAN not only involves NFs, but also all IF types examined to date, in neuronal and non-neuronal cells. Those alterations extend to GFAP, NFs, keratin, desmin, and vimentin in human and suggest a key role for gigaxonin in maintaining IF architecture.</p>
          <p>Skin-derived primary fibroblasts of affected individuals revealed abnormal aggregation of vimentin as an ovoid mass visible on electron or light microscope examination [<xref ref-type="bibr" rid="gan.REF.pena.1983.227">Pena et al 1983</xref>]. This human-derived cell type represents a valuable cellular model to study IF organization in GAN. Studies on multiple fibroblasts revealed that vimentin aggregation is partial and conditional, is aggravated upon MT destabilization [<xref ref-type="bibr" rid="gan.REF.bomont.2003.813">Bomont &#x00026; Koenig 2003</xref>], and does not depend on TBCB, a partner of gigaxonin [<xref ref-type="bibr" rid="gan.REF.cleveland.2009.1384">Cleveland et al 2009</xref>].</p>
        </sec>
        <sec id="gan.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>GAN pathogenic variants are scattered over the entire gene, and clear correlations between specific <italic toggle="yes">GAN</italic> pathogenic variants and particular phenotypic characteristics have not been reported. </p>
        </sec>
        <sec id="gan.Prevalence">
          <title>Prevalence</title>
          <p>GAN is a very rare disorder; the true prevalence is not known. To date, about 50 families have been reported worldwide; see, for example: <xref ref-type="bibr" rid="gan.REF.bomont.2000.370">Bomont et al [2000]</xref>, <xref ref-type="bibr" rid="gan.REF.kuhlenbaumer.2002.1273">Kuhlenb&#x000e4;umer et al [2002]</xref>, <xref ref-type="bibr" rid="gan.REF.bomont.2003.446">Bomont et al [2003]</xref>, <xref ref-type="bibr" rid="gan.REF.bruno.2004.13">Bruno et al [2004]</xref>, and <xref ref-type="bibr" rid="gan.REF.demir.2005.825">Demir et al [2005]</xref>.</p>
        </sec>
      </sec>
      <sec id="gan.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with mutation of <italic toggle="yes">GAN</italic>.</p>
      </sec>
      <sec id="gan.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Severe early-onset <bold>autosomal recessive hereditary neuropathies</bold> (i.e., those classified as <related-object link-type="booklink" source-id="gene" document-id="cmt4" document-type="chapter">Charcot-Marie-Tooth hereditary neuropathy type 4</related-object> [CMT4]) may be considered in the differential diagnosis of giant axonal neuropathy (GAN), especially in the (rare) absence of both the characteristic hair abnormalities and prominent CNS abnormalities. (In the past the term Dejerine-Sottas syndrome was used to designate severe childhood-onset genetic neuropathies of any inheritance; the term is no longer in general use [see <related-object link-type="booklink" source-id="gene" document-id="cmt" document-type="chapter">CMT overview</related-object>].)</p>
        <p>CMT4 is a genetically heterogeneous disorder inherited in an autosomal recessive manner. Ten subtypes caused by mutation of one of ten genes are recognized:</p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="cmt-4a" document-type="chapter"><bold>CMT4A</bold></related-object> comprises a peripheral neuropathy typically affecting the lower extremities earlier and more severely than the upper extremities. As the neuropathy progresses, the distal upper extremities also become severely affected. Even proximal muscles can become weak. The age at onset ranges from infancy to early childhood. In most cases, disease progression causes disabilities within the first or second decade of life. The neuropathy can be either of the demyelinating type with reduced NCVs or the axonal type with normal NCVs. Vocal cord paresis is common. The disease is caused by mutation of <italic toggle="yes">GDAP1</italic>. </p>
          </list-item>
          <list-item>
            <p><bold>CMT4B</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/601382">601382</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/604563">604563</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/615284">615284</ext-link>), characterized by myelin outfoldings seen on nerve biopsy, is caused by mutation of <italic toggle="yes">MTMR2</italic> (CMT4B1), <italic toggle="yes">SBF2</italic> (CMT4B2), or <italic toggle="yes">SBF1</italic> (CMT4B3). </p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="cmt4c" document-type="chapter"><bold>CMT4C</bold></related-object> is a demyelinating neuropathy characterized by early-onset severe spine deformities. The majority of affected children present with scoliosis or kyphoscoliosis between ages two and ten years. CMT4C is caused by mutation of <italic toggle="yes">SH3TC2</italic>. Although the presence of giant axons and neurofilament (NF) accumulation in the nerve biopsy are usually indicative of GAN, this diagnosis is excluded by further clinical investigation and identification of biallelic pathogenic variants in <italic toggle="yes">SH3TC2</italic>.</p>
          </list-item>
          <list-item>
            <p><bold>CMT4E</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/605253">605253</ext-link>) has been described in a few families with autosomal recessive severe congenital hypomyelinating neuropathy and is caused by biallelic pathogenic variants of <italic toggle="yes">EGR2</italic>. </p>
          </list-item>
        </list>
        <p><related-object link-type="booklink" source-id="gene" document-id="menkes" document-type="chapter"><bold><italic toggle="yes">ATP7A</italic>-related distal motor neuropathy</bold></related-object>, an adult-onset distal motor neuropathy, is allelic with Menkes disease and occipital horn syndrome.</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="menkes" document-type="chapter"><bold>Menkes disease</bold></related-object> is a rare X-linked recessive disorder with prominent CNS involvement and hair changes resembling those of GAN. Menkes disease is a disorder of copper transport caused by pathogenic <italic toggle="yes">ATP7A</italic>. Serum copper concentration and serum ceruloplasmin concentration are low. Infants with classic Menkes disease appear healthy until age two to three months, when loss of developmental milestones, hypotonia, seizures, and failure to thrive occur. The diagnosis is usually suspected when infants exhibit typical neurologic changes and concomitant characteristic changes of the hair (short, sparse, coarse, twisted, often lightly pigmented). Temperature instability and hypoglycemia may be present in the neonatal period. Death usually occurs by age three years. </p>
        <p><related-object link-type="booklink" source-id="gene" document-id="inad" document-type="chapter"><bold>Classic infantile neuroaxonal dystrophy</bold></related-object> (INAD or Seitelberger disease) is an infantile-onset disease of the CNS and peripheral nervous system with neurologic symptoms resembling GAN but without the characteristic hair changes of GAN. A characteristic pathologic feature is the presence of axonal spheroids made of vesiculotubular structures, tubular membranous material with clefts; these axonal spheroids are found in both the CNS and the peripheral nervous system, including the cutaneous or conjunctival nerve twigs. Pathogenic variants in <italic toggle="yes">PLA2G6</italic> (encoding phospholipase A2) were demonstrated in persons with INAD [<xref ref-type="bibr" rid="gan.REF.morgan.2006.752">Morgan et al 2006</xref>]. The study, however, did not find pathogenic variants in <italic toggle="yes">PLA2G6</italic> in all affected individuals tested, suggesting either incomplete detection of pathogenic variants or genetic heterogeneity. </p>
        <p><related-object link-type="booklink" source-id="gene" document-id="mld" document-type="chapter"><bold>Arylsulfatase A deficiency</bold></related-object> (ARSA deficiency, metachromatic leukodystrophy, MLD) is a disorder of impaired breakdown of sulfatides that occur throughout the body but are found in greatest abundance in nervous tissue, kidneys, and testes. Onset ranges from late infancy to adulthood. <italic toggle="yes">ARSA</italic> is the only gene in which mutation is associated with the disorder. Inheritance is autosomal recessive. </p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Late-infantile MLD.</bold> Onset is between ages one and two years. Typical presenting signs include weakness, hypotonia, clumsiness, frequent falls, toe walking, and slurred speech. Later signs include inability to stand, difficulty speaking, deterioration of mental function, increased muscle tone, pain in the arms and legs, generalized or partial seizures, compromised vision and hearing, and peripheral neuropathy. The final stages include tonic spasms, decerebrate posturing with rigidly extended extremities, feeding by gastrostomy tube, blindness, and general unawareness of surroundings. Expected life span is about 3.5 years after onset of symptoms but can be up to ten or more years with current treatment approaches. </p>
          </list-item>
          <list-item>
            <p><bold>Juvenile MLD.</bold> Onset is between age four years and sexual maturity (age 12-14 years). Initial manifestations include decline in school performance and emergence of behavioral problems, followed by clumsiness, gait problems, slurred speech, incontinence, and bizarre behaviors. Seizures, more commonly partial seizures, may occur. Expected life span is ten to 20 or more years after diagnosis. </p>
          </list-item>
          <list-item>
            <p><bold>Adult MLD.</bold> Onset occurs after sexual maturity; therefore, it would not be confused with GAN. </p>
          </list-item>
        </list>
        <p>Several <bold>neurotoxic substances</bold> (e.g., n-hexane and acrylamide) cause a mixed axonal and demyelinating peripheral neuropathy with axonal swelling and NF accumulation. Toxicity from n-hexane can result from occupational exposure or, rarely, from recreational gasoline vapor inhalation [<xref ref-type="bibr" rid="gan.REF.chang.1998.964">Chang et al 1998</xref>]. However, chronic exposure to these toxic substances is extremely unlikely in children around the age of onset of GAN, therefore excluding this type of neurotoxicity as a risk factor for GAN. </p>
      </sec>
      <sec id="gan.Management">
        <title>Management</title>
        <sec id="gan.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and the needs of an individual diagnosed with giant axonal neuropathy (GAN), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Assessment of development/cognitive abilities to establish the extent of disease and monitor progression or attempted intervention</p>
            </list-item>
            <list-item>
              <p>Medical genetics consultation</p>
            </list-item>
          </list>
          <p>The following investigations may be used to confirm clinically apparent problems but also to uncover subclinical involvement of PNS and CNS lesions which are not clinically apparent:</p>
          <list list-type="bullet">
            <list-item>
              <p>Clinical and electrophysiologic (sensory and motor NCVs, electromyography) examination of the peripheral motor and sensory nervous system (including assessment of the function of cranial nerves) to establish the extent of disease and monitor progression </p>
            </list-item>
            <list-item>
              <p>Neuroophthalmologic examination to look for nystagmus resulting from cerebellar dysfunction or strabismus caused by involvement of cranial nerves III, IV, or VI </p>
            </list-item>
            <list-item>
              <p>EEG, somatosensory and motor evoked potentials, and brain MRI to determine the degree of CNS involvement</p>
            </list-item>
          </list>
        </sec>
        <sec id="gan.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Treatment, focused on managing the clinical findings, often involves a team including (pediatric) neurologists, orthopedic surgeons, physiotherapists, psychologists, and speech and occupational therapists. Major goals are to optimize intellectual and physical development and, later in life, to slow the inevitable deterioration of these capacities.</p>
          <p>Note: Early intellectual development is nearly normal in many affected children, enabling them to attend a normal school initially; however, significant intellectual impairment usually occurs before the second decade of life.</p>
          <p>Treatment includes the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Speech and occupational therapy to improve communication and activities of daily living </p>
            </list-item>
            <list-item>
              <p>Early intervention and special education directed to the individual's disability. Frequent reassessment is needed because of the progressive nature of the disorder. Special education often becomes necessary between ages five and 12 years. </p>
            </list-item>
            <list-item>
              <p>Physiotherapy (typically for distal weakness, ataxia, and spasticity) to preserve mobility as long as possible </p>
            </list-item>
            <list-item>
              <p>Orthopedic surgery as required for foot deformities (Note, however, that most affected individuals become wheelchair bound between ages ten and 20 years for other reasons.) </p>
            </list-item>
            <list-item>
              <p>Appropriate ophthalmologic treatment (e.g., surgery or glasses), especially if diplopia occurs </p>
            </list-item>
          </list>
        </sec>
        <sec id="gan.Prevention_of_Secondary_Complication">
          <title>Prevention of Secondary Complications</title>
          <p>Wheelchair-bound or bedridden patients require frequent examination for decubitus ulcers and appropriate prophylaxis. </p>
        </sec>
        <sec id="gan.Surveillance">
          <title>Surveillance</title>
          <p>The following should be monitored in persons with GAN:</p>
          <list list-type="bullet">
            <list-item>
              <p>Intellectual development/deterioration </p>
            </list-item>
            <list-item>
              <p>Progression of the peripheral neuropathy, ataxia, spasticity, and cranial nerve dysfunction </p>
            </list-item>
          </list>
          <p>The frequency of the monitoring should depend on disease progression; annual or more frequent evaluation is recommended.</p>
        </sec>
        <sec id="gan.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="gan.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="gan.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="gan.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="gan.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Giant axonal neuropathy (GAN) is inherited in an autosomal recessive manner. </p>
        </sec>
        <sec id="gan.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p><bold>Parents of a proband</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes and therefore carry one <italic toggle="yes">GAN</italic> pathogenic variant. </p>
            </list-item>
            <list-item>
              <p>Heterozygotes are asymptomatic, but can display mild axonal neuropathy, as revealed by moderate reduction of nerve action potential amplitudes [<xref ref-type="bibr" rid="gan.REF.demir.2005.825">Demir et al 2005</xref>]. </p>
            </list-item>
          </list>
          <p><bold>Sibs of a proband</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. </p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the chance of his/her being a carrier is 2/3. </p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic. </p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> No individuals with GAN are known to have reproduced. </p>
          <p><bold>Other family members.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier. </p>
        </sec>
        <sec id="gan.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">GAN</italic> pathogenic variants in the family.</p>
          <p>Note: Some unaffected carriers (heterozygotes) can show mild axonal neuropathy, as revealed by moderate reduction of nerve action potential amplitudes [<xref ref-type="bibr" rid="gan.REF.demir.2005.825">Demir et al 2005</xref>].</p>
        </sec>
        <sec id="gan.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy. </p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals. </p>
        </sec>
        <sec id="gan.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the <italic toggle="yes">GAN</italic> pathogenic variants have been identified in an affected family member, prenatal testing for pregnancies at increased risk may be available from a clinical laboratory that offers either testing of this gene or custom prenatal testing.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the <italic toggle="yes">GAN</italic> pathogenic variants have been identified. </p>
        </sec>
      </sec>
      <sec id="gan.Resources">
        <title>Resources</title>
      </sec>
      <sec id="gan.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold> The full <italic toggle="yes">GAN</italic> cDNA (AF291673) is 4677 nt long with an open reading frame of 1791 nt encoding a protein of 597 amino acids (AAG35311.1) [<xref ref-type="bibr" rid="gan.REF.bomont.2000.370">Bomont et al 2000</xref>]. <italic toggle="yes">GAN</italic> is organized in 11 exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="gan" object-id="gan.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Benign allelic variants.</bold>
<xref ref-type="bibr" rid="gan.REF.bomont.2000.370">Bomont et al [2000]</xref> described two normal variants within the coding sequence (see <xref ref-type="table" rid="gan.T.benign_variants_in_the_gan_coding_">Table 2</xref>).</p>
        <table-wrap id="gan.T.benign_variants_in_the_gan_coding_" position="anchor" orientation="portrait">
          <label>Table 2.</label>
          <caption>
            <p>Benign Variants in the <italic toggle="yes">GAN</italic> Coding Sequence</p>
          </caption>
          <table>
            <tbody>
              <tr>
                <th id="hd_b_gan.T.benign_variants_in_the_gan_coding__1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Exon</th>
                <th id="hd_b_gan.T.benign_variants_in_the_gan_coding__1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">Nucleotide Change</th>
                <th id="hd_b_gan.T.benign_variants_in_the_gan_coding__1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">Amino Acid Change</th>
                <th id="hd_b_gan.T.benign_variants_in_the_gan_coding__1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">Approximate Frequency</th>
                <th id="hd_b_gan.T.benign_variants_in_the_gan_coding__1_1_1_5" align="left" valign="middle" rowspan="1" colspan="1">Reference Sequence</th>
              </tr>
              <tr>
                <td headers="hd_b_gan.T.benign_variants_in_the_gan_coding__1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">8</td>
                <td headers="hd_b_gan.T.benign_variants_in_the_gan_coding__1_1_1_2" align="left" valign="middle" rowspan="1" colspan="1">c.1293C&#x0003e;T</td>
                <td headers="hd_b_gan.T.benign_variants_in_the_gan_coding__1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">p.=&#x000a0;<sup>1</sup><break/>(Tyr431Tyr)&#x000a0;<sup>2</sup>
</td>
                <td headers="hd_b_gan.T.benign_variants_in_the_gan_coding__1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">35%</td>
                <td headers="hd_b_gan.T.benign_variants_in_the_gan_coding__1_1_1_5" align="left" valign="middle" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_071324.1">NP_071324.1</ext-link>
                </td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="gan.TF.2">
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants. </p>
            </fn>
            <fn id="gan.TF.2.1">
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature. </p>
            </fn>
            <fn id="gan.TF.2.2">
              <p>1. p.= designates that protein has not been analyzed, but no change is expected.</p>
            </fn>
            <fn id="gan.TF.2.3">
              <p>2. Variant designation that does not conform to current naming conventions</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Pathogenic allelic variants.</bold> Pathogenic variants in <italic toggle="yes">GAN</italic> (<related-object source-id="gene" document-id="gan" object-id="gan.molgen.TA">Table A</related-object>) were first reported by <xref ref-type="bibr" rid="gan.REF.bomont.2000.370">Bomont et al [2000]</xref> and later by <xref ref-type="bibr" rid="gan.REF.kuhlenbaumer.2002.1273">Kuhlenb&#x000e4;umer et al [2002]</xref>, <xref ref-type="bibr" rid="gan.REF.bomont.2003.446">Bomont et al [2003]</xref>, <xref ref-type="bibr" rid="gan.REF.bruno.2004.13">Bruno et al [2004]</xref>, <xref ref-type="bibr" rid="gan.REF.demir.2005.825">Demir et al [2005]</xref>, and others. To date a total of 47 pathogenic variants have been identified in 49 families of diverse geographic origins, in all <italic toggle="yes">GAN</italic> exons and including all types of mutations: nonsense, missense, insertion, and splice site; and deletions that can encompass several exons.</p>
        <p>Most currently known <italic toggle="yes">GAN</italic> pathogenic variants are listed in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.molgen.ua.ac.be/CMTMutations/">Mutation Database of Inherited Peripheral Neuropathies</ext-link> [<xref ref-type="bibr" rid="gan.REF.nelis.1999.11">Nelis et al 1999</xref>]. (See <related-object source-id="gene" document-id="gan" object-id="gan.molgen.TA">Table A</related-object>.) </p>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">GAN</italic> encodes for gigaxonin, a new BTB-Kelch protein named by the authors to refer to the giant axons present in the pathology [<xref ref-type="bibr" rid="gan.REF.bomont.2000.370">Bomont et al 2000</xref>].</p>
        <p>The development of specific antibodies for gigaxonin revealed its low and preferential expression in neuronal tissues and during embryogenesis in mouse [<xref ref-type="bibr" rid="gan.REF.bomont.2003.446">Bomont et al 2003</xref>, <xref ref-type="bibr" rid="gan.REF.ganay.2011.25">Ganay et al 2011</xref>].</p>
        <p>Its N-terminus BTB domain (<italic toggle="yes">b</italic>road-complex, <italic toggle="yes">t</italic>ramtrack and <italic toggle="yes">b</italic>ric a brac domain) mediates homodimerization of gigaxonin [<xref ref-type="bibr" rid="gan.REF.cullen.2004.873">Cullen et al 2004</xref>] and its C-terminal Kelch domain is composed of six Kelch repeats [<xref ref-type="bibr" rid="gan.REF.bomont.2000.370">Bomont et al 2000</xref>]. </p>
        <p>The resolution of the crystal structure of another BTB-Kelch protein [<xref ref-type="bibr" rid="gan.REF.li.2004.54750">Li et al 2004</xref>] confirmed the predicted tertiary structure conserved in Kelch proteins, namely a beta-propeller. Whereas Kelch repeats display a high variability in sequence, their three-dimensional organization exposes multiple surfaces for protein-protein interaction with partners that likely determine Kelch protein function. Thus, through interaction with distinct proteins, the Kelch-repeat superfamily is involved in many aspects of the cell function, including coordination of cell morphology, differentiation and growth, regulation of oxidative stress, and contribution to viral pathogenesis [<xref ref-type="bibr" rid="gan.REF.adams.2000.17">Adams et al 2000</xref>]. </p>
        <p>BTB-containing proteins (including gigaxonin) have been shown to be part of an enzymatic complex involved in the clearance of unfolded/short-lived proteins, namely E3 ubiquitin ligase [<xref ref-type="bibr" rid="gan.REF.furukawa.2003.1001">Furukawa et al 2003</xref>]. Interacting with the Cul3 subunit of the E3 ligase through the BTB domain and with partners through the Kelch domain, gigaxonin would be the substrate adaptor of this E3 ligase, allowing the degradation of specific substrates by the proteasome subsequent to addition of a ubiquitin chain. Supporting this hypothesis, an excess of gigaxonin has been shown to completely destroy several intermediate filament networks (including vimentin and neurofilaments) in cells, through interaction with gigaxonin and by a mechanism involving the proteasome [<xref ref-type="bibr" rid="gan.REF.mahammad.2013.1964">Mahammad et al 2013</xref>]. </p>
        <p>Through its Kelch domain, gigaxonin has been shown to interact with three proteins involved in microtubule (MT) homeostasis and dynamics: the MT-associated proteins MAP1B and MAP1S and the tubulin chaperone TBCB [<xref ref-type="bibr" rid="gan.REF.ding.2002.427">Ding et al 2002</xref>, <xref ref-type="bibr" rid="gan.REF.allen.2005.224">Allen et al 2005</xref>, <xref ref-type="bibr" rid="gan.REF.wang.2005.2050">Wang et al 2005</xref>, <xref ref-type="bibr" rid="gan.REF.ding.2006.1451">Ding et al 2006</xref>]. In overexpression systems, their abundance is regulated by gigaxonin via a process of ubiquitination. The role of MAP1B, MAP1S, and TBCB in neurodegeneration and intermediate filament aggregation has been investigated in cellular models for GAN. Whereas gigaxonin depletion in embryonic cortical neurons derived from a mouse knockout model resulted in massive neuronal death, the contribution of MAP1B and MAP1S to neuronal death is moderate [<xref ref-type="bibr" rid="gan.REF.allen.2005.224">Allen et al 2005</xref>, <xref ref-type="bibr" rid="gan.REF.ding.2006.1451">Ding et al 2006</xref>]. Unlike its counterpart TBCE, the tubulin chaperon TBCB has been shown to modestly destabilize MTs and is not responsible for the vimentin aggregation in fibroblasts derived from affected individuals [<xref ref-type="bibr" rid="gan.REF.cleveland.2009.1384">Cleveland et al 2009</xref>]. </p>
        <p>Altogether, these studies suggest that the known substrates are not playing an important role in GAN and that the key effectors of gigaxonin have still to be identified. </p>
        <p><bold>Mouse model.</bold> A GAN mouse model has been attempted; gigaxonin has been depleted by gene disruption of the promotor and exon 1 [<xref ref-type="bibr" rid="gan.REF.dequen.2008.253">Dequen et al 2008</xref>] and in exons 3-5 [<xref ref-type="bibr" rid="gan.REF.ding.2006.1451">Ding et al 2006</xref>, <xref ref-type="bibr" rid="gan.REF.ganay.2011.25">Ganay et al 2011</xref>]. Mouse models show a mild form of the disease, with late onset and mild behavioral deficits and no giant axons. </p>
        <list list-type="bullet">
          <list-item>
            <p>The GAN<sup>&#x02206;exon1</sup> model did not have an overt neurologic phenotype or neuronal loss; it exhibited modest hind-limb muscle atrophy, a 10% decrease of muscle innervation, and a 27% loss of motor axons at age six months [<xref ref-type="bibr" rid="gan.REF.dequen.2008.253">Dequen et al 2008</xref>]. </p>
          </list-item>
          <list-item>
            <p>Motor and sensory deficits, evaluated over time with different behavioral tests in the GAN<sup>ex3-5</sup> mouse model have revealed late (&#x02265;1 year), modest but persistent motor deficits in the murine 129/SvJ-genetic background, while sensory impairment was found in C57BL/6 animals [<xref ref-type="bibr" rid="gan.REF.ganay.2011.25">Ganay et al 2011</xref>]. </p>
          </list-item>
        </list>
        <p>Aggregation of NFs was observed in the GAN mouse models and its quantification revealed a dramatically increased abundance of NFs in neuronal tissues [<xref ref-type="bibr" rid="gan.REF.dequen.2008.253">Dequen et al 2008</xref>, <xref ref-type="bibr" rid="gan.REF.ganay.2011.25">Ganay et al 2011</xref>]. Ultrastructural examination of gigaxonin-depleted axons showed the massive disorganization of NFs seen in human: an altered orientation along the axons, and increased diameter [<xref ref-type="bibr" rid="gan.REF.ganay.2011.25">Ganay et al 2011</xref>]. </p>
        <p>Overall, the GAN mouse models fail to reproduce the severity of disease found in humans but recapitulate the NF aggregation characteristic of the human pathology.</p>
        <p><bold>Abnormal gene product.</bold>
<italic toggle="yes">GAN</italic> pathogenic variants are distributed over the entire gene and lead to a decreased abundance of gigaxonin, as revealed by immunodetection of gigaxonin in several lymphoblast cell lines derived from unrelated patients [<xref ref-type="bibr" rid="gan.REF.cleveland.2009.1384">Cleveland et al 2009</xref>]. </p>
        <p>A study of the effects of the mutations in several patients revealed that decreased amounts of gigaxonin are caused by a general mechanism of instability of either the transcript (for biallelic nonsense mutations or deletions) or the tri-dimensional structure of the protein [<xref ref-type="bibr" rid="gan.REF.boizot.2014.1">Boizot et al 2014</xref>]. </p>
        <p>Regarding the proposed function of gigaxonin as an E3 ligase adaptor, gigaxonin deficiency would impede ubiquitin-mediated protein degradation of its partners: MAP1B-LC, MAP8, TBCB, and probably other unidentified proteins. Identifying the substrates of gigaxonin will be essential to advance the understanding of GAN disease pathogenicity. </p>
      </sec>
      <sec id="gan.References">
        <title>References</title>
        <sec id="gan.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="gan.Literature_Cited.reflist0">
            <ref id="gan.REF.adams.2000.17">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelso</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cooley</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <article-title>The kelch repeat superfamily of proteins: propellers of cell function.</article-title>
                <source>Trends Cell Biol</source>
                <year>2000</year>
                <volume>10</volume>
                <fpage>17</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">10603472</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.alkan.2003.371">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Alkan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kutlu</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sigirci</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baysal</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Altinok</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yakinci</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Giant axonal neuropathy: MRS findings.</article-title>
                <source>J Neuroimaging</source>
                <year>2003</year>
                <volume>13</volume>
                <fpage>371</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">14569833</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.allen.2005.224">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Allen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ding</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pramanik</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chou</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yau</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <article-title>Gigaxonin-controlled degradation of MAP1B light chain is critical to neuronal survival.</article-title>
                <source>Nature</source>
                <year>2005</year>
                <volume>438</volume>
                <fpage>224</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16227972</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.asbury.1972.237">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Asbury</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gale</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cox</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baringer</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berg</surname>
                    <given-names>BO</given-names>
                  </name>
                </person-group>
                <article-title>Giant axonal neuropathy--a unique case with segmental neurofilamentous masses.</article-title>
                <source>Acta Neuropathol.</source>
                <year>1972</year>
                <volume>20</volume>
                <fpage>237</fpage>
                <lpage>47</lpage>
                <pub-id pub-id-type="pmid">5044004</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.benhamida.1990.245">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ben Hamida</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hentati</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben Hamida</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Giant axonal neuropathy with inherited multisystem degeneration in a Tunisian kindred.</article-title>
                <source>Neurology.</source>
                <year>1990</year>
                <volume>40</volume>
                <fpage>245</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">2153943</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.berg.1972.894">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Berg</surname>
                    <given-names>BO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenberg</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asbury</surname>
                    <given-names>AK</given-names>
                  </name>
                </person-group>
                <article-title>Giant axonal neuropathy.</article-title>
                <source>Pediatrics.</source>
                <year>1972</year>
                <volume>49</volume>
                <fpage>894</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">4339350</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.boizot.2014.1">
              <mixed-citation publication-type="book">Boizot A, Talmat-Amar Y, Morrogh D, Kuntz NL, Halbert C, Chabrol B, Houlden H, Stojkovic T, Schulman BA, Rautenstrauss B, Bomont P (2014). The instability of the BTB-KELCH protein Gigaxonin causes Giant Axonal Neuropathy and constitutes a new penetrant and specific diagnostic test. Acta Neuropathol Commun. 24;2:47.</mixed-citation>
            </ref>
            <ref id="gan.REF.bomont.2000.370">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bomont</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cavalier</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blondeau</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben Hamida</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Belal</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tazir</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Demir</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Topaloglu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korinthenberg</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tuysuz</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landrieu</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hentati</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koenig</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy.</article-title>
                <source>Nat Genet</source>
                <year>2000</year>
                <volume>26</volume>
                <fpage>370</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">11062483</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.bomont.2003.446">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bomont</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ioos</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yalcinkaya</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korinthenberg</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vallat</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Assami</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chabrol</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurlemann</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tazir</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koenig</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Identification of seven novel mutations in the GAN gene.</article-title>
                <source>Hum Mutat</source>
                <year>2003</year>
                <volume>21</volume>
                <fpage>446</fpage>
                <pub-id pub-id-type="pmid">12655563</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.bomont.2003.813">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bomont</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koenig</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Intermediate filament aggregation in fibroblasts of giant axonal neuropathy patients is aggravated in non dividing cells and by microtubule destabilization.</article-title>
                <source>Hum Mol Genet.</source>
                <year>2003</year>
                <volume>12</volume>
                <fpage>813</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">12668605</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.brockmann.2003.45">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brockmann</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pouwels</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dechent</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flanigan</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frahm</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanefeld</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Cerebral proton magnetic resonance spectroscopy of a patient with giant axonal neuropathy.</article-title>
                <source>Brain Dev.</source>
                <year>2003</year>
                <volume>25</volume>
                <fpage>45</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">12536033</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.bruno.2004.13">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bruno</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Federico</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tonoli</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lispi</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cassandrini</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pedemonte</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santorelli</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filocamo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dotti</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schenone</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malandrini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minetti</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Clinical and molecular findings in patients with giant axonal neuropathy (GAN).</article-title>
                <source>Neurology</source>
                <year>2004</year>
                <volume>62</volume>
                <fpage>13</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">14718689</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.buysse.2010.2802">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Buysse</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vergult</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mussche</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ceuterick-de Groote</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Speleman</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Menten</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lissens</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Coster</surname>
                    <given-names>R.</given-names>
                  </name>
                </person-group>
                <article-title>Giant axonal neuropathy caused by compound heterozygosity for a maternally inherited microdeletion and a paternal mutation within the GAN gene.</article-title>
                <source>Am J Med Genet A.</source>
                <year>2010</year>
                <volume>152A</volume>
                <issue>11</issue>
                <fpage>2802</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">20949505</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.chang.1998.964">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chang</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>England</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sumner</surname>
                    <given-names>AJ</given-names>
                  </name>
                </person-group>
                <article-title>Focal conduction block in n-hexane polyneuropathy.</article-title>
                <source>Muscle Nerve</source>
                <year>1998</year>
                <volume>21</volume>
                <fpage>964</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">9626263</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.cleveland.2009.1384">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cleveland</surname>
                    <given-names>DW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamanaka</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bomont</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Gigaxonin controls vimentin organization through a tubulin chaperone-independent pathway.</article-title>
                <source>Hum Mol Genet.</source>
                <year>2009</year>
                <volume>18</volume>
                <fpage>1384</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">19168853</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.cullen.2004.873">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cullen</surname>
                    <given-names>VC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brownlees</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Banner</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anderton</surname>
                    <given-names>BH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leigh</surname>
                    <given-names>PN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shaw</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>CC</given-names>
                  </name>
                </person-group>
                <article-title>Gigaxonin is associated with the Golgi and dimerises via its BTB domain.</article-title>
                <source>Neuroreport</source>
                <year>2004</year>
                <volume>15</volume>
                <fpage>873</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15073534</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.demir.2005.825">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Demir</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bomont</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erdem</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cavalier</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Demirci</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kose</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muftuoglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cakar</surname>
                    <given-names>AN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tan</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aysun</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Topcu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guicheney</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koenig</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Topaloglu</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Giant axonal neuropathy: clinical and genetic study in six cases.</article-title>
                <source>J Neurol Neurosurg Psychiatry</source>
                <year>2005</year>
                <volume>76</volume>
                <fpage>825</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">15897506</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.dequen.2008.253">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dequen</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bomont</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gowing</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cleveland</surname>
                    <given-names>DW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Julien</surname>
                    <given-names>JP</given-names>
                  </name>
                </person-group>
                <article-title>Modest loss of peripheral axons, muscle atrophy and formation of brain inclusions in mice with targeted deletion of gigaxonin exon 1.</article-title>
                <source>J Neurochem.</source>
                <year>2008</year>
                <volume>107</volume>
                <fpage>253</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">18680552</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.ding.2006.1451">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ding</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valle</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nardine</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cui</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeon</surname>
                    <given-names>NL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>So</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vogel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tolwani</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mobley</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <article-title>Gene targeting of GAN in mouse causes a toxic accumulation of microtubule-associated protein 8 and impaired retrograde axonal transport.</article-title>
                <source>Hum Mol Genet</source>
                <year>2006</year>
                <volume>15</volume>
                <fpage>1451</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">16565160</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.ding.2002.427">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ding</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kowal</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nardine</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhattacharya</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <article-title>Microtubule-associated protein 1B: a neuronal binding partner for gigaxonin.</article-title>
                <source>J Cell Biol.</source>
                <year>2002</year>
                <volume>158</volume>
                <fpage>427</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">12147674</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.donaghy.1988.991">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Donaghy</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brett</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ormerod</surname>
                    <given-names>IE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>PK</given-names>
                  </name>
                </person-group>
                <article-title>Giant axonal neuropathy: observations on a further patient.</article-title>
                <source>J Neurol Neurosurg Psychiatry.</source>
                <year>1988</year>
                <volume>51</volume>
                <fpage>991</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">2849642</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.furukawa.2003.1001">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Furukawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>He</surname>
                    <given-names>YJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Borchers</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xiong</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <article-title>Targeting of protein ubiquitination by BTB-Cullin 3-Roc1 ubiquitin ligases.</article-title>
                <source>Nat Cell Biol.</source>
                <year>2003</year>
                <volume>5</volume>
                <fpage>1001</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">14528312</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.ganay.2011.25">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ganay</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boizot</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burrer</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chauvin</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bomont</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Sensory-motor deficits and neurofilament disorganization in gigaxonin-null mice.</article-title>
                <source>Mol Neurodegener.</source>
                <year>2011</year>
                <volume>6</volume>
                <fpage>25</fpage>
                <pub-id pub-id-type="pmid">21486449</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.kaler.2011.15">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kaler</surname>
                    <given-names>SG</given-names>
                  </name>
                </person-group>
                <article-title>ATP7A-related copper transport diseases-emerging concepts and future trends.</article-title>
                <source>Nat Rev Neurol.</source>
                <year>2011</year>
                <volume>7</volume>
                <fpage>15</fpage>
                <lpage>29</lpage>
                <pub-id pub-id-type="pmid">21221114</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.kennerson.2010.343">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kennerson</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicholson</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaler</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kowalski</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mercer</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Llanos</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takata</surname>
                    <given-names>RI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Speck-Martins</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baets</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Almeida-Souza</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timmerman</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scherer</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferguson</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bird</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Jonghe</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feely</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shy</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garbern</surname>
                    <given-names>JY</given-names>
                  </name>
                </person-group>
                <article-title>Missense mutations in the copper transporter gene ATP7A cause X-linked distal hereditary motor neuropathy.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2010</year>
                <volume>86</volume>
                <fpage>343</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">20170900</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.kuhlenbaumer.2002.1273">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kuhlenb&#x000e4;umer</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oberwittler</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>H&#x000fc;nermund</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schirmacher</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Domschke</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ringelstein</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>St&#x000f6;gbauer</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Giant axonal neuropathy (GAN): case report and two novel mutations in the gigaxonin gene.</article-title>
                <source>Neurology.</source>
                <year>2002</year>
                <volume>58</volume>
                <fpage>1273</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">11971098</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.li.2004.54750">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hannink</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beamer</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <article-title>Crystal structure of the Kelch domain of human Keap1.</article-title>
                <source>J Biol Chem.</source>
                <year>2004</year>
                <volume>279</volume>
                <fpage>54750</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15475350</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.mahammad.2013.1964">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mahammad</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murthy</surname>
                    <given-names>SN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Didonna</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grin</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Israeli</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perrot</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bomont</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Julien</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuczmarski</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Opal</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldman</surname>
                    <given-names>RD</given-names>
                  </name>
                </person-group>
                <article-title>Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation.</article-title>
                <source>J Clin Invest.</source>
                <year>2013</year>
                <volume>123</volume>
                <fpage>1964</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">23585478</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.morgan.2006.752">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Morgan</surname>
                    <given-names>NV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Westaway</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morton</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregory</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gissen</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sonek</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cangul</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coryell</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Canham</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nardocci</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zorzi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasha</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodriguez</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desguerre</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mubaidin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trembath</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simonati</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schanen</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levinson</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woods</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilmot</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kramer</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gitschier</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maher</surname>
                    <given-names>ER</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayflick</surname>
                    <given-names>SJ</given-names>
                  </name>
                </person-group>
                <article-title>PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron.</article-title>
                <source>Nat Genet.</source>
                <year>2006</year>
                <volume>38</volume>
                <fpage>752</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">16783378</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.nelis.1999.11">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nelis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haites</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Broeckhoven</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in the peripheral myelin genes and associated genes in inherited peripheral neuropathies.</article-title>
                <source>Hum Mutat.</source>
                <year>1999</year>
                <volume>13</volume>
                <fpage>11</fpage>
                <lpage>28</lpage>
                <pub-id pub-id-type="pmid">9888385</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.pena.1983.227">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pena</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Opas</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turksen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalnins</surname>
                    <given-names>VI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carpenter</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Immunocytochemical studies of intermediate filament aggregates and their relationship to microtubules in cultured skin fibroblasts from patients with giant axonal neuropathy.</article-title>
                <source>Eur J Cell Biol.</source>
                <year>1983</year>
                <volume>31</volume>
                <issue>2</issue>
                <fpage>227</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">6315439</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.wang.2005.2050">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ding</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhu</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vogel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>Y.</given-names>
                  </name>
                </person-group>
                <article-title>Gigaxonin interacts with tubulin folding cofactor B and controls its degradation through the ubiquitin-proteasome pathway.</article-title>
                <source>Curr Biol.</source>
                <year>2005</year>
                <volume>15</volume>
                <fpage>2050</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16303566</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.yi.2012.1794">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donsante</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kennerson</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mercer</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garbern</surname>
                    <given-names>JY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaler</surname>
                    <given-names>SG</given-names>
                  </name>
                </person-group>
                <article-title>Altered intracellular localization and valosin-containing protein (p97 VCP) interaction underlie ATP7A-related distal motor neuropathy.</article-title>
                <source>Hum Mol Genet.</source>
                <year>2012</year>
                <volume>21</volume>
                <fpage>1794</fpage>
                <lpage>807</lpage>
                <pub-id pub-id-type="pmid">22210628</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.zemmouri.2000.592">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zemmouri</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Azzedine</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Assami</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kitouni</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vallat</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maisonobe</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamadouche</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kessaci</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mansouri</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Guern</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grid</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tazir</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Charcot-Marie-Tooth 2-like presentation of an Algerian family with giant axonal neuropathy.</article-title>
                <source>Neuromuscul Disord.</source>
                <year>2000</year>
                <volume>10</volume>
                <fpage>592</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11053687</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="gan.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="gan.Suggested_Reading.reflist0">
            <ref id="gan.REF.akagi.2012.156">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Akagi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mohri</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iwatani</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kagitani-Shimono</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okinaga</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakai</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozono</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taniike</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Clinicogenetical features of a Japanese patient with giant axonal neuropathy.</article-title>
                <source>Brain Dev.</source>
                <year>2012</year>
                <volume>34</volume>
                <fpage>156</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">21356581</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.brenner.2008.236">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brenner</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Speck-Martins</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farage</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barker</surname>
                    <given-names>PB</given-names>
                  </name>
                </person-group>
                <article-title>3T MR with diffusion tensor imaging and single-voxel spectroscopy in giant axonal neuropathy.</article-title>
                <source>J Magn Reson Imaging.</source>
                <year>2008</year>
                <volume>28</volume>
                <fpage>236</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">18581347</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.buysse.2010.2802.Suggested_R.3">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Buysse</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vergult</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mussche</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ceuterick-de Groote</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Speleman</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Menten</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lissens</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Coster</surname>
                    <given-names>R.</given-names>
                  </name>
                </person-group>
                <article-title>Giant axonal neuropathy caused by compound heterozygosity for a maternally inherited microdeletion and a paternal mutation within the GAN gene.</article-title>
                <source>Am J Med Genet.</source>
                <year>2010</year>
                <volume>152A</volume>
                <fpage>2802</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">20949505</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.cleveland.2009.1384.Suggeste.4">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cleveland</surname>
                    <given-names>DW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamanaka</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bomont</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Gigaxonin controls vimentin organization through a tubulin chaperone-independent pathway.</article-title>
                <source>Hum Mol Genet.</source>
                <year>2009</year>
                <volume>18</volume>
                <fpage>1384</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">19168853</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.houlden.2007.1267">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Houlden</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groves</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miedzybrodzka</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roper</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willis</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cole</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reilly</surname>
                    <given-names>MM</given-names>
                  </name>
                </person-group>
                <article-title>New mutations, genotype phenotype studies and manifesting carriers in giant axonal neuropathy.</article-title>
                <source>J Neurol Neurosurg Psychiatry.</source>
                <year>2007</year>
                <volume>78</volume>
                <fpage>1267</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">17578852</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.koop.2007.624">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Koop</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schirmacher</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timmerman</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Jonghe</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ringelstein</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rasic</surname>
                    <given-names>VM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evrard</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000e4;rtner</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Claeys</surname>
                    <given-names>KG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Appenzeller</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rautenstrauss</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>H&#x000fc;hne</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramos-Arroyo</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>W&#x000f6;rle</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moilanen</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hammans</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuhlenb&#x000e4;umer</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Genotype-phenotype analysis in patients with giant axonal neuropathy (GAN).</article-title>
                <source>Neuromuscul Disord.</source>
                <year>2007</year>
                <volume>17</volume>
                <fpage>624</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">17587580</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.kuhlenbaumer.2008.276">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kuhlenb&#x000e4;umer</surname>
                    <given-names>G.</given-names>
                  </name>
                </person-group>
                <article-title>Genotype-phenotype analysis in patients with giant axonal neuropathy.</article-title>
                <source>Neuromuscul Disord.</source>
                <year>2008</year>
                <volume>18</volume>
                <fpage>276</fpage>
                <pub-id pub-id-type="pmid">18343115</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.leung.2007.6">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Leung</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shu</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goryunov</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liem</surname>
                    <given-names>RK</given-names>
                  </name>
                </person-group>
                <article-title>Alterations in lipid metabolism gene expression and abnormal lipid accumulation in fibroblast explants from giant axonal neuropathy patients.</article-title>
                <source>BMC Genet.</source>
                <year>2007</year>
                <volume>8</volume>
                <fpage>6</fpage>
                <pub-id pub-id-type="pmid">17331252</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.nalini.2008.426">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nalini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gayathri</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yasha</surname>
                    <given-names>TC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ravishankar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Urtizberea</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huehne</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rautenstrauss</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>Clinical, pathological and molecular findings in two siblings with giant axonal neuropathy (GAN): report from India.</article-title>
                <source>Eur J Med Genet.</source>
                <year>2008</year>
                <volume>51</volume>
                <fpage>426</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">18595793</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.ravishankar.2009.181">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ravishankar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goel</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rautenstrauss</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nalini</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Spectrum of magnetic resonance imaging findings in a family with giant axonal neuropathy confirmed by genetic studies.</article-title>
                <source>Neurol India.</source>
                <year>2009</year>
                <volume>57</volume>
                <fpage>181</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">19439850</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.tazir.2009.270">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tazir</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nouioua</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magy</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huehne</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Assami</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Urtizberea</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grid</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamadouche</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rautenstrauss</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vallat</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <article-title>Phenotypic variability in giant axonal neuropathy.</article-title>
                <source>Neuromuscul Disord.</source>
                <year>2009</year>
                <volume>19</volume>
                <fpage>270</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">19231187</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.vasudev.2010.119">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vasudev</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhat</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bharath</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prasad</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arvinda</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kulkarni</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gayathri</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Giant axonal neuropathy: a pictorial essay and review of literature.</article-title>
                <source>The Neuroradiology Journal.</source>
                <year>2010</year>
                <volume>232</volume>
                <fpage>119</fpage>
                <lpage>25</lpage>
              </element-citation>
            </ref>
            <ref id="gan.REF.yang.2007.601">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ding</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>W.</given-names>
                  </name>
                </person-group>
                <article-title>Giant axonal neuropathy</article-title>
                <source>Cell Mol Life Sci.</source>
                <year>2007</year>
                <volume>64</volume>
                <fpage>601</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">17256086</pub-id>
              </element-citation>
            </ref>
            <ref id="gan.REF.zhang.2009.1552">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>LP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zou</surname>
                    <given-names>LP</given-names>
                  </name>
                </person-group>
                <article-title>Clinical and genetic studies in a Chinese family with giant axonal neuropathy.</article-title>
                <source>J Child Neurol.</source>
                <year>2009</year>
                <volume>24</volume>
                <fpage>1552</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">19295179</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="gan.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="gan.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>9 October 2014 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>21 June 2012 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>11 August 2009 (cd) Revision: sequence analysis available clinically</p>
            </list-item>
            <list-item>
              <p>2 July 2007 (me) Comprehensive update posted to live Web site </p>
            </list-item>
            <list-item>
              <p>28 February 2005 (me) Comprehensive update posted to live Web site </p>
            </list-item>
            <list-item>
              <p>9 January 2003 (me) Review posted to live Web site </p>
            </list-item>
            <list-item>
              <p>5 August 2002 (vt) Original submission </p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
